Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (University of Helsinki)
- Development stage
- Unknown
- Lead developer
- University of Helsinki
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
Autologous bone marrow-derived mesenchymal stem cells (MSCs) represent a cell therapy approach developed by the University of Helsinki for treating ischemic heart failure. The therapeutic process involves the extraction of bone marrow from the patient's iliac crest, followed by the isolation of MSCs using Ficoll density gradient centrifugation. These cells are then administered via intramyocardial injection directly into the heart tissue during coronary artery bypass grafting (CABG) surgery. The primary objective of this intervention is to enhance myocardial function and promote tissue regeneration in patients with a history of myocardial infarction and significant left ventricular dysfunction (LVEF 15-45%). The therapy is hypothesized to work through paracrine mechanisms that stimulate angiogenesis and reduce fibrotic remodeling.
- Other names
- autologous mesenchymal stem cellsBM-MSCsbone marrow-derived mesenchymal cells
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (University of Helsinki).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (University of Helsinki).